Molecular genetic factors of oncogenesis associated with the Epstein–Barr virus

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Epstein–Barr virus (EBV) is a human herpesvirus type 4, which is carried by the majority of the world’s population. Its etiologic role in the development of various lymphomas, nasopharyngeal cancer, gastric cancer, and other malignancies has been proven. The mechanisms and participants of EBV-associated oncogenesis are actively studied. This review describes the molecular genetic diversity of EBV associated with the development of cancer. A literature review revealed that EBV is characterized by high structural and functional diversity of nucleotide and amino acid sequences. Based on polymorphism of EBV genes EBNA-1, EBNA-2, EBNA-LP, EBER, BZLF1, LMP-2A and LMP-1, various mutations, types, and variants, associated with malignant transformation and the development of various cancer types were identified.

Aim. To summarize and analyze literature data devoted to the study of the genetic diversity of EBV for the prospective development of molecular biological research methodology in clinical practice, as well as the development of diagnostic tools, specific prevention and therapy of EBV-associated oncological diseases based on the products of the viral genome.

About the authors

Nikolay A. Sakharnov

Academician I.N. Blokhina Nizhny Novgorod Scientific Research Institute of Epidemiology and Microbiology of Rospotrebnadzor (Russian Federal Consumer Rights Protection and Human Health Control Service)

Author for correspondence.
Email: sakharnov_n@mail.ru
ORCID iD: 0000-0003-3965-2033
SPIN-code: 8457-3501
Scopus Author ID: 55386076100
ResearcherId: AAF-7673-2020
Russian Federation, 603950, Nizhny Novgorod, Malaya Yamskaya St.,71

Oleg V. Utkin

Academician I.N. Blokhina Nizhny Novgorod Scientific Research Institute of Epidemiology and Microbiology, Federal Service for the Oversight of Consumer Protection and Welfare

Email: utkino2004@mail.ru
ORCID iD: 0000-0002-7571-525X
Russian Federation, 71 Malaya Yamskaya St., Nizhny Novgorod 603950

Sergey P. Dmitriev

Research Institute of Clinical Oncology “Nizhny Novgorod Regional Clinical Oncology Dispensary”

Email: sergei-fcsm@yandex.ru
ORCID iD: 0009-0008-1051-882X
Russian Federation, 11/1 Delovaya St., Nizhny Novgorod 603163

Elena N. Filatova

Academician I.N. Blokhina Nizhny Novgorod Scientific Research Institute of Epidemiology and Microbiology, Federal Service for the Oversight of Consumer Protection and Welfare

Email: el.filatova83@mail.ru
ORCID iD: 0000-0002-6683-7191
Russian Federation, 71 Malaya Yamskaya St., Nizhny Novgorod 603950

Svyatoslav V. Zinoviev

Research Institute of Clinical Oncology “Nizhny Novgorod Regional Clinical Oncology Dispensary”

Email: swet.ssk@yandex.ru
ORCID iD: 0000-0003-1037-2601
Russian Federation, 11/1 Delovaya St., Nizhny Novgorod 603163

Nikita A. Suslov

Academician I.N. Blokhina Nizhny Novgorod Scientific Research Institute of Epidemiology and Microbiology, Federal Service for the Oversight of Consumer Protection and Welfare

Email: suslovnikita98gr@gmail.com
ORCID iD: 0009-0006-1407-6884
Russian Federation, 71 Malaya Yamskaya St., Nizhny Novgorod 603950

Sergey V. Gamayunov

Research Institute of Clinical Oncology “Nizhny Novgorod Regional Clinical Oncology Dispensary”

Email: gamajnovs@mail.ru
ORCID iD: 0000-0002-0223-0753
Russian Federation, 11/1 Delovaya St., Nizhny Novgorod 603163

References

  1. Epstein M.A., Achong B.G., Barr Y.M. Virus particles in cultured lymphoblasts from Burkitt’s lymphoma. Lancet 1964;1(7335):702–3. doi: 10.1016/s0140-6736(64)91524-7
  2. Kanda T., Yajima M., Ikuta K. Epstein–Barr virus strain variation and cancer. Cancer Sci 2019;110(4):1132–9. doi: 10.1111/cas.13954
  3. Crawford D.H. Biology and disease associations of Epstein–Barr virus. Philos Trans R Soc Lond B Biol Sci 2001;356(1408):461–73 doi: 10.1098/rstb.2000.0783
  4. Yakushina S.A., Kisteneva L.B. Influence of the Epstein–Barr virus persistence upon the development of the immune-mediated somatic diseases. Rossiyskiy vestnik perinatologii i pediatrii = Russian Bulletin of Perinatology and Pediatrics 2018;63(1):22–7. (In Russ.). doi: 10.21508/1027-4065-2018-63-1-22-27
  5. Epstein–Barr virus and Kaposi’s sarcoma herpesvirus/human herpesvirus 8. Lyon (FR): International Agency for Research on Cancer. 1997. 492 p.
  6. Yushchuk N.D., Shestakova I.V. Epstein–Barr virus associated with newgrowth: clinical, immunophenotypic and immuno-citomorphological characteristic (analytical review). Infectious diseases: news, opinions, education 2013;3:33–47. (In Russ.).
  7. Wong Y., Meehan M.T., Burrows S.R. et al. Estimating the global burden of Epstein–Barr virus-related cancers. J Cancer Res Clin Oncol 2022;148(1):31–46. doi: 10.1007/s00432-021-03824-y
  8. Ressing M.E., van Gent M., Gram A.M. et al. Immune evasion by Epstein–Barr virus. Curr Top Microbiol Immunol 2015;391: 355–81. doi: 10.1007/978-3-319-22834-1_12
  9. Chakravorty S., Afzali B., Kazemian M. EBV-associated diseases: current therapeutics and emerging technologies. Front Immunol 2022;13:1059133. doi: 10.3389/fimmu.2022.1059133
  10. Xiao Q., Liu Y., Li T. et al. Viral oncogenesis in cancer: from mechanisms to therapeutics. Signal Transduct Target Ther 2025;10(1):151. doi: 10.1038/s41392-025-02197-9
  11. Yakushina S.A., Kisteneva L.B. Epstein–Barr virus (Herpesviridae: Gammaherpesvirinae: Lymphocryptovirus: Human gammaherpesvirus 4): replicative strategies. Voprosy virusologii = Problems of Virology 2020;65(4):191–202. (In Russ.). doi: 10.36233/0507-4088-2020-65-4-191-202
  12. Kaira A.N., Solomai T.V., Semenenko T.A. Epidemiology and prevention of Epstein–Barr Virus infection: a textbook. Moscow: Russian Medical Academy of Continuous Professional Education of the Ministry of Health of the Russian Federation, 2022. 81 p. (In Russ.).
  13. Johannsen E.C., Kaye K.M. Epstein–Barr virus (infectious mononucleosis, Epstein–Barr virus-associated malignant diseases, and other diseases). Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 7th edn. Philadelphia: Elsevier, 2010. Pp. 1989–2010. doi: 10.1016/B978-0-443-06839-3.00139-9
  14. Unger E., Purtilo D.T. Epstein–Barr virus and human diseases. Pathology of infectious diseases. Ed. by D.H. Connor, F.W. Chandler, H.J. Manz et al. Stamford: Appleton and Lange, 1997. Pp. 113–123.
  15. Rezk S.A., Weiss L.M. Epstein–Barr virus-associated lymphoproliferative disorders. Hum Pathol 2007;38(9):1293–304. doi: 10.1016/j.humpath.2007.05.020
  16. Tran H., Nourse J., Hall S. et al. Immunodeficiency-associated lymphomas. Blood Rev 2008;22(5):261–81. doi: 10.1016/j.blre.2008.03.009
  17. Gurtsevich V. The role of Epstein–Barr virus in human hematopoietic neoplasms. Clinicheskaya oncogematologia = Clinical oncohematology 2010;3(3):222–34. (In Russ.).
  18. Arvin A., Campadelli-Fiume G., Mocarski E. et al. Herpesviruses: biology, therapy, and immunoprophylaxis. Cambridge: Cambridge University Press, 2007.
  19. Baer R., Bankier A.T., Biggin M.D. et al. DNA sequence and expression of the B95-8 Epstein–Barr virus genome. Nature 1984;310:207–11.
  20. Santpere G., Darre F., Blanco S. et al. Genome-wide analysis of wild-type Epstein–Barr virus genomes derived from healthy individuals of the 1,000 Genomes Project. Genome Biol Evol 2014;6(4):846–60. doi: 10.1093/gbe/evu054
  21. Human gammaherpesvirus 4 genomes. Available at: https://www.ncbi.nlm.nih.gov/datasets/genome/?taxon = 10376
  22. Kim S.M., Kang S.H., Lee W.K. Identification of two types of naturally-occurring intertypic recombinants of Epstein–Barr virus. Mol Cells 2006;21(2):302–7.
  23. Palser A.L., Grayson N.E., White R.E. et al. Genome diversity of Epstein–Barr virus from multiple tumor types and normal infection. J Virol 2015;89(10):5222–37. doi: 10.1128/JVI.03614-14
  24. Weiss E.R., Lamers S.L., Henderson J.L. et al. Early Epstein–Barr virus genomic diversity and convergence toward the B95.8 genome in primary infection. J Virol 2018;92(2):e01466–17. doi: 10.1128/JVI.01466-17
  25. Zhou L., Chen J.N., Qiu X.M. et al. Comparative analysis of 22 Epstein–Barr virus genomes from diseased and healthy individuals. J Gen Virol 2017;98(1):96–107. doi: 10.1099/jgv.0.000699
  26. Zanella L., Riquelme I., Buchegger K. et al. A reliable Epstein–Barr virus classification based on phylogenomic and population analyses. Sci Rep 2019 8;9(1):9829. doi: 10.1038/s41598-019-45986-3
  27. Yakovleva L.S., Senyuta N.B., Goncharova E.V. et al. Epstein–Barr virus LMP1 oncogene variants in cell lines of different origin. Molecularnaya biologia = Molecular Biology 2015;49(5):800–10. (In Russ.). doi: 10.7868/S0026898415050213
  28. Neves M., Marinho-Dias J., Ribeiro J., Sousa H. Epstein–Barr virus strains and variations: geographic or disease-specific variants? J Med Virol 2017;89(3):373–87. doi: 10.1002/jmv.24633
  29. Abdel-Hamid M., Chen J.J., Constantine N. et al. EBV strain variation: geographical distribution and relation to disease state. Virology 1992;190:168–75. doi: 10.1016/0042-6822(92)91202-6
  30. Kimura H., Ito Y., Kawabe S. et al. EBV-associated T/NK-cell lymphoproliferative diseases in nonimmunocompromised hosts: prospective analysis of 108 cases. Blood 2012;119(3):673–86. doi: 10.1182/blood-2011-10-381921
  31. Wegner F., Lassalle F., Depledge D.P. Coevolution of Sites under Immune Selection Shapes Epstein–Barr Virus Population Structure. Mol Biol Evol 2019;36(11):2512–21. doi: 10.1093/molbev/msz152
  32. Fruscalzo A., Marsili G., Busiello V. et al. DNA sequence heterogeneity within the Epstein–Barr virus family of repeats in the latent origin of replication. Gene 2001;265(1–2):165–73. doi: 10.1016/s0378-1119(01)00345-6
  33. Ba Abdullah M.M., Palermo R.D., Palser A.L. et al. Heterogeneity of the Epstein–Barr virus (EBV) major internal repeat reveals evolutionary mechanisms of EBV and a functional defect in the prototype EBV strain B95-8. J Virol 2017;91:e00920–17. doi: 10.1128/JVI.00920-17
  34. Tierney R.J., Kao K.Y., Nagra J.K. et al. Epstein–Barr virus BamHI W repeat number limits EBNA2/EBNA-LP coexpression in newly infected B cells and the efficiency of B-cell transformation: a rationale for the multiple W repeats in wild-type virus strains. J Virol 2011;85(23):12362–75. doi: 10.1128/JVI.06059-11
  35. Kudin A.P. This “harmless” Epstein–Barr virus infection. Part 1. Characteristics of the pathogen. The immune system’s response to the virus. Meditsinskie novosti = Medical News 2006;7:14–22. (In Russ.).
  36. Fu Q., He C., Mao Z.R. Epstein–Barr virus interactions with the Bcl-2 protein family and apoptosis in human tumor cells. J Zhejiang Univ Sci B 2013;14(1):8–24. doi: 10.1631/jzus.B1200189
  37. Bhatia K., Raj A., Guitierrez M.I. et al. Variation in the sequence of Epstein Barr virus nuclear antigen 1 in normal peripheral blood lymphocytes and in Burkitt’s lymphomas. Oncogene 1996;13(1);177–81.
  38. Habeshaw G., Yao Q.Y., Bell A.I. et al. Epstein–Barr virus nuclear antigen 1 sequences in endemic and sporadic Burkitt’s lymphoma reflect virus strains prevalent in different geographic areas. J Virol 1999;73(2):965–75. doi: 10.1128/JVI.73.2.965-975.1999
  39. Smatti M.K., Yassine H.M., AbuOdeh R. et al. Prevalence and molecular profiling of Epstein Barr virus (EBV) among healthy blood donors from different nationalities in Qatar. PLoS One 2017;12(12):e0189033. doi: 10.1371/journal.pone.0189033
  40. White R.E., Rämer P.C., Naresh K.N. et al. EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors. J Clin Invest 2012;122(4):1487–502. doi: 10.1172/JCI58092
  41. Lo A.K., Dawson C.W., Jin D.Y., Lo K.W. The pathological roles of BART miRNAs in nasopharyngeal carcinoma. J Pathol 2012;227(4):392–403. doi: 10.1002/path.4025
  42. Hui K.F., Chan T.F., Yang W. et al. High risk Epstein–Barr virus variants characterized by distinct polymorphisms in the EBER locus are strongly associated with nasopharyngeal carcinoma. Int J Cancer 2019;144(12):3031–42. doi: 10.1002/ijc.32049
  43. Wu Y., Maruo S., Yajima M. et al. Epstein–Barr virus (EBV)-encoded RNA 2 (EBER2) but not EBER1 plays a critical role in EBV-induced B-cell growth transformation. J Virol 2007;81(20):11236–45. doi: 10.1128/JVI.00579-07
  44. Martini M., Capello D., Serraino D. et al. Characterization of variants in the promoter of EBV gene BZLF1 in normal donors, HIV-positive patients and in AIDS-related lymphomas. J Infect 2007;54(3):298–306. doi: 10.1016/j.jinf.2006.04.015
  45. Farrell P.J. Epstein–Barr virus strain variation. Curr Top Microbiol Immunol 2015;390(1):45–69. doi: 10.1007/978-3-319-22822-8_4
  46. Tzellos S., Farrell P.J. Epstein–Barr virus sequence variation-biology and disease. Pathogens 2012;1(2):156–74. doi: 10.3390/pathogens1020156
  47. Banko A.V., Lazarevic I.B., Folic M.M. et al. Characterization of the variability of Epstein–Barr virus genes in nasopharyngeal biopsies: potential predictors for carcinoma progression. PLoS One 2016;11(4):e0153498. doi: 10.1371/journal.pone.0153498
  48. Alanazi A.E., Alhumaidy A.A., Almutairi H. et al. Evolutionary analysis of LMP-1 genetic diversity in EBV-associated nasopharyngeal carcinoma: Bioinformatic insights into oncogenic potential. Infect Genet Evol 2024;120:105586. doi: 10.1016/j.meegid.2024.105586
  49. Smatti M.K., Al-Sadeq D.W., Ali N.H. et al. Epstein–Barr virus epidemiology, serology, and genetic variability of LMP-1 oncogene among healthy population: an update. Front Oncol 2018;8:211. doi: 10.3389/fonc.2018.00211
  50. Li S.N., Chang Y.S., Liu S.T. Effect of a 10-amino acid deletion on the oncogenic activity of latent membrane protein 1 of Epstein–Barr virus. Oncogene 1996;12(10):2129–35.
  51. Mainou B.A., Raab-Traub N. LMP1 strain variants: biological and molecular properties. J Virol 2006;80(13):6458–68. doi: 10.1128/JVI.00135-06
  52. Kang M.S., Kieff E. Epstein–Barr virus latent genes. Exp Mol Med 2015;47(1):e131. doi: 10.1038/emm.2014.84
  53. Zeng M.S., Li D.J., Liu Q.L. et al. Genomic sequence analysis of Epstein–Barr virus strain GD1 from a nasopharyngeal carcinoma patient. J Virol 2005;79(24):15323–30. doi: 10.1128/JVI.79.24.15323-15330.2005
  54. Pai P.C., Tseng C.K., Chuang C.C. et al. Polymorphism of C-terminal activation region 2 of Epstein–Barr virus latent membrane protein 1 in predicting distant failure and post-metastatic survival in patients with nasopharyngeal carcinoma. Head Neck 2007;29(2):109–19. doi: 10.1002/hed.20483
  55. Trinh C.T.H., Tran D.N., Nguyen L.T.T. et al. LMP1-EBV gene deletion mutations and HLA genotypes of nasopharyngeal cancer patients in Vietnam. Pathophysiology 2023;30(1):1–12. doi: 10.3390/pathophysiology30010001
  56. Montes-Mojarro I.A., Fend F., Quintanilla-Martinez L. EBV and the pathogenesis of NK/T Cell Lymphoma. Cancers (Basel) 2021;13(6):1414. doi: 10.3390/cancers13061414
  57. Smirnova K.V., Diduk S.V., Gurtsevitch V.E. Polymorphism of Epstein–Barr virus LMP1 oncogene in nanaians, representatives of indigenous minority of the Russian far East. Epidemiologiya i infektsionnye bolezni = Epidemiology and Infectious Diseases 2017;22(5):239–47. (In Russ.). doi: 10.1882/1560-9529-2017-22-5-239-247
  58. Diduk S.V., Smirnova K.V., Pavlish О.А., Gurtsevitch V.E. Functionally significant mutations in Epstein–Barr virus LMP1 gene and their role in activation of cell signaling pathways. Biochimia = Biochemistry 2008;73(10):1414–21. (In Russ.).
  59. Sample J.T., Sample C.E. Epstein–Barr virus: molecular biology. In: Encyclopedia of virology. Oxford: Academic Press, 2008. Pp. 157–167.
  60. Kirchmaier A.L., Sugden B. Dominant-negative inhibitors of EBNA-1 of Epstein–Barr virus. J Virol 1997;71(3):1766–75. doi: 10.1128/JVI.71.3.1766-1775.1997
  61. Li J.S.Z., Abbasi A., Kim D.H. et al. Chromosomal fragile site breakage by EBV-encoded EBNA1 at clustered repeats. Nature 2023;616(7957):504–9. doi: 10.1038/s41586-023-05923-x
  62. Sandvej K., Zhou X.G., Hamilton-Dutoit S. EBNA-1 sequence variation in Danish and Chinese EBV-associated tumours: evidence for geographical polymorphism but not for tumour-specific subtype restriction. J Pathol 2000;191(2):127–31. doi: 10.1002/(SICI)1096-9896(200006)191:2< 127::AID-PATH614>3.0.CO;2-E
  63. Choi S.J., Jung S.W., Huh S. et al. Phylogenetic comparison of Epstein–Barr virus genomes. J Microbiol 2018;56:525–33. doi: 10.1007/s12275-018-8039-x
  64. Kelly G., Bell A., Rickinson A. Epstein–Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2. Nat Med 2002;8(10):1098–104. doi: 10.1038/nm758
  65. Dambaugh T., Hennessy K., Chamnankit L. et al. U2 region of Epstein–Barr virus DNA may encode Epstein–Barr nuclear antigen 2. Proc Natl Acad Sci USA 1984;81(23):7632–6. doi: 10.1073/pnas.81.23.7632
  66. Rowe M., Young L.S., Cadwallader K. et al. Distinction between Epstein–Barr virus type A (EBNA 2A) and type B (EBNA 2B) isolates extends to the EBNA 3 family of nuclear proteins. J Virol 1989;63(3):1031–9. doi: 10.1128/JVI.63.3.1031-1039.1989.
  67. Sample J., Young L., Martin B. et al. Epstein–Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes. J Virol 1990;64(9):4084–92. doi: 10.1128/JVI.64.9.4084-4092.1990
  68. Tsai M.H., Lin X., Shumilov A. et al. The biological properties of different Epstein–Barr virus strains explain their association with various types of cancers. Oncotarget 2017;8(6):10238–54. doi: 10.18632/oncotarget.14380
  69. Gurtsevitch V.E., Lubenskaya A.K., Senyuta N.B., Smirnova K.V. Epstein–Barr virus (Orthoherpesviridae: Lymphocryptovirus) among Russian ethnic groups: prevalence of EBV types (EBV-1 and EBV-2), LMP1 gene variants and malignancies. Voprosy Virusologii = Problems of Virology 2024;69(1):56–64. (In Russ.). doi: 10.36233/0507-4088-214
  70. Lubenskaya A.K., Smirnova K.V., Gurtsevich V.E. Molecular markers of EBV-associated nasopharyngeal cancer in Russia. Voprosy oncologii = Issues of oncology 2023;69(3S):545–546. (In Russ.). doi: 10.37469/0507-3758-2023-69-3s1
  71. Smirnova K.V., Lubenskaya A.K., Senyuta N.B. et al. Epstein–Barr virus (Herpesviridae: Lymphocryptovirus) types 1 and 2 and other viral markers in nasopharyngeal carcinoma patients in two geographically and ethnically different regions of Russia. Voprosy Virusologii = Problems of Virology 2023;68(4):291–301. (In Russ.). doi: 10.36233/0507-4088-181
  72. Al-Mozaini M., Bodelon G., Karstegl C.E. et al. Epstein–Barr virus BART gene expression. J Gen Virol 2009;90(2):307–16. doi: 10.1099/vir.0.006551-0
  73. Lin X., Tsai M.H., Shumilov A. et al. The Epstein–Barr virus BART miRNA cluster of the M81 strain modulates multiple functions in primary B cells. PLoS Pathog 2015;11(12):e1005344. doi: 10.1371/journal.ppat.1005344
  74. Sergeeva N.S., Marshutina N.V., Solokhina M.P. et al. Epstein–Barr virus-associated solid malignancies. Onkologiya. Zhurnal im. P.A. Gertsena = P.A. Herzen Journal of Oncology 2018;7(5):80–9. (In Russ.). doi: 10.17116/onkolog2018705180
  75. Kieff E., Rickinson A.B. Epstein–Barr virus and its replication. In: Field’s virology. Philadelphia: Lippincott Williams & Wilkins, 2007. Pp. 2603–2654.
  76. Ma S.D., Hegde S., Young K.H. et al. A new model of Epstein–Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas. J Virol 2011;85(1):165–77. doi: 10.1128/JVI.01512-10
  77. Gutiérrez M.I., Ibrahim M.M., Dale J.K. et al. Discrete alterations in the BZLF1 promoter in tumor and non-tumor-associated Epstein–Barr virus. J Natl Cancer Inst 2002;94(23):1757–63. doi: 10.1093/jnci/94.23.1757
  78. Bristol J.A., Djavadian R., Albright E.R. et al. A cancer-associated Epstein–Barr virus BZLF1 promoter variant enhances lytic infection. PLoS Pathog 2018;14:e1007179. doi: 10.1371/journal.ppat.1007179
  79. Tsai M.H., Raykova A., Klinke O. et al. Spontaneous lytic replication and epitheliotropism define an Epstein–Barr virus strain found in carcinomas. Cell Rep 2013;5(2):458–70. doi: 10.1016/j.celrep.2013.09.012
  80. Swart R., Ruf I.K., Sample J. et al. Latent membrane protein 2A-mediated effects on the phosphatidylinositol 3-kinase/Akt pathway. J Virol 2000;74(22):10838–45. doi: 10.1128/jvi.74.22.10838-10845.2000
  81. Moody C.A., Scott R.S., Amirghahari N. et al. Modulation of the cell growth regulator mTOR by Epstein–Barr virus-encoded LMP2A. J Virol 2005;79(9):5499–506. doi: 10.1128/JVI.79.9.5499-5506.2005
  82. Wang Y., Rong Y., Yang L., Lu Z. Genetic variability and mutation of Epstein‒Barr virus (EBV)-encoded LMP-1 and BHRF-1 genes in EBV-infected patients: identification of precise targets for development of personalized EBV vaccines. Virus Genes 2023;59(4):541–53. doi: 10.1007/s11262-023-02006-x
  83. Begic V., Korac P., Gasparov S. et al. Molecular characterisation of Epstein–Barr virus in classical Hodgkin Lymphoma. Int J Mol Sci 2022;23(24):15635. doi: 10.3390/ijms232415635
  84. Bouvard V., Baan R., Straif K. et al. A review of human carcinogens – part B: biological agents. Lancet Oncol 2009;10 (4):321–2. doi: 10.1016/s1470-2045(09)70096-8
  85. Fierti A.O., Yakass M.B., Okertchiri E.A. et al. The role of Epstein–Barr virus in modulating key tumor suppressor genes in associated malignancies: epigenetics, transcriptional, and post-translational modifications. Biomolecules 2022;12(1):127. doi: 10.3390/biom12010127
  86. Dirmeier U., Neuhierl B., Kilger E. et al. Latent membrane protein 1 is critical for efficient growth transformation of human B cells by Epstein–Barr virus. Cancer Res 2003;63:2982–89.
  87. Edwards R.H., Seillier-Moiseiwitsch F., Raab-Traub N. Signature amino acid changes in latent membrane protein 1 distinguish Epstein–Barr virus strains. Virology 1999;261(1):79–95. doi: 10.1006/viro.1999.9855
  88. Sarshari B., Mohebbi S.R., Ravanshad M. et al. Sequence variations of Epstein–Barr virus LMP1 gene in gastric cancer and chronic gastritis isolates from Iranian patients. Gastroenterol Hepatol Bed Bench 2022;15(3):225–31. doi: 10.22037/ghfbb.v15i3.2578
  89. Goncharova E.V., Senyuta N.B., Smirnova K.V. et al. Epstein–Barr virus (EBV) in Russia: infection of the population and analysis of the LMP1 gene variants in patients with EBV-associated pathologies and healthy individuals. Voprosy virusologii = Issues of Virology 2015;60(2):11–7. (In Russ.).
  90. Gurtsevich V.E., Smirnova K.V., Diduk S.V. et al. Polymorphism of the LMP1 gene in patients with EBV-negative forms of gastric cancer. Voprosy virusologii = Problems of virology 2010;55(5):29–34. (In Russ.).
  91. Walling D.M., Brown A.L., Etienne W. et al. Multiple Epstein–Barr virus infections in healthy individuals. J Virol 2003;77(11):6546–50. doi: 10.1128/jvi.77.11.6546-6550.2003
  92. Saechan V., Mori A., Mitarnun W. et al. Analysis of LMP1 variants of EBV in Southern Thailand: evidence for strain-associated T-cell tropism and pathogenicity. J Clin Virol 2006;36(2):119–25. doi: 10.1016/j.jcv.2006.01.018
  93. Nguyen-Van D., Ernberg I., Phan-Thi Phi P. et al. Epstein–Barr virus genetic variation in Vietnamese patients with nasopharyngeal carcinoma: full-length analysis of LMP1. Virus Genes 2008;37(2):273–81. doi: 10.1007/s11262-008-0262-9
  94. Smirnova K.V., Senyuta N.B., Lubenskaya A.K. et al. Ancient variants of the Epstein–Barr virus (Herpesviridae, Lymphocryptovirus, HHV-4): hypotheses and facts. Voprosy Virusologii = Problems of Virology 2020;65(2):77–86. (In Russ.). doi: 10.36233/0507-4088-2020-65-2-77-86
  95. Gurtsevitch V.E., Smirnova K.V., Botezatu I.V. et al. Epstein–Barr virus LMP1 oncogene polymorphism in tatar and slavic populations in Russian Federation impacting on some malignant tumours. Infektsiya i immunitet = Russian Journal of Infection and Immunity 2020;10(2):347–58. (In Russ.). doi: 10.15789/2220-7619-EBV-1162
  96. Smirnova K.V., Senyuta N.B., Botezatu I.V. et al. Epstein–Barr virus in the ethnic Tatars population: the infection and sequence variants of LMP1 oncogene. Uspekhi molekulyarnoy onkologii = Advances in Molecular Oncology 2018;5(3):65–74. (In Russ.). doi: 10.17650/2313-805X-2018-5-3-65-74
  97. Jen K.Y., Cheng J., Li J. et al. Mutational events in LMP1 gene of Epstein–Barr virus in salivary gland lymphoepithelial carcinomas. Int J Cancer 2003;105(5):654–60. doi: 10.1002/ijc.11100
  98. Hu L.F., Zabarovsky E.R., Chen F. et al. Isolation and sequencing of the Epstein–Barr virus BNLF-1 gene (LMP1) from a Chinese nasopharyngeal carcinoma. J Gen Virol 1991;72(10):2399–409. doi: 10.1099/0022-1317-72-10-2399
  99. Su Z.Y., Siak P.Y., Leong C.O. et al. The role of Epstein–Barr virus in nasopharyngeal carcinoma. Front Microbiol 2023;14:1116143. doi: 10.3389/fmicb.2023.1116143
  100. Hadhri-Guiga B., Khabir A.M., Mokdad-Gargouri R. et al. Various 30 and 69 bp deletion variants of the Epstein–Barr virus LMP1 may arise by homologous recombination in nasopharyngeal carcinoma of Tunisian patients. Virus Res 2006;115(1):24–30. doi: 10.1016/j.virusres.2005.07.002
  101. Dardari R., Khyatti M., Cordeiro P. et al. High frequency of latent membrane protein-1 30-bp deletion variant with specific single mutations in Epstein–Barr virus-associated nasopharyngeal carcinoma in Moroccan patients. Int J Cancer 2006;118 (8):1977–83. doi: 10.1073/pnas.81.23.7632
  102. Popkova M.I., Utkin O.V. Features of the current epidemic process of infectious mononucleosis in the Nizhny Novgorod Region. Zdorov’e naseleniya i sreda obitaniya = Public Health and Habitat 2021;4(337):79–86. (In Russ.). doi: 10.35627/22195238/202133747986
  103. Corvalan A., Ding S., Koriyama C. et al. Association of a distinctive strain of Epstein–Barr virus with gastric cancer. Int J Cancer 2006;118(7):1736–42. doi: 10.1002/ijc.21530
  104. Corvalán A.H., Ruedlinger J., de Mayo T. et al. The phylogeographic diversity of EBV and admixed ancestry in the americas another model of disrupted human-pathogen co-evolution. Cancers (Basel) 2019;11(2):217. doi: 10.3390/cancers11020217
  105. Lung M.L., Chang R.S., Huang M.L. et al. Epstein–Barr virus genotypes associated with nasopharyngeal carcinoma in southern China. Virology 1990;177(1):44–53. doi: 10.1016/0042-6822(90)90458-4
  106. Ordonez P., Koriyama C., Ding S. et al. Identification of the distinctive type i/XhoI+ strain of Epstein–Barr virus in gastric carcinoma in Peru. Anticancer Res 2011;31(10):3607–13.
  107. Lee A.W.M., Lee V.H.F., Ng W.T. et al. A systematic review and recommendations on the use of plasma EBV DNA for nasopharyngeal carcinoma. Eur J Cancer 2021;153:109–22. doi: 10.1016/j.ejca.2021.05.022
  108. Chen W.J., Xu W.N., Wang H.Y. et al. Plasma Epstein–Barr virus DNA and risk of nasopharyngeal carcinoma in a prospective seropositive population. BMC Cancer 2021;21(1):651. doi: 10.1186/s12885-021-08408-0
  109. Smirnova K.V., Senuta N.B., Botezatu I.V. et al. Markers of Epstein–Barr virus in clinical assessment of Russian patients with nasopharyngeal cancer. Uspekhi molekulyarnoy onkologii = Advances in Molecular Oncology 2021;8(3):14–24. (In Russ.). doi: 10.17650/2313-805X-2021-8-3-14-24
  110. Vasilyeva A.S., Molchanov A.D. Molecular markers and development of methods for early diagnosis of EBV-associated gastric cancer. Voprosy oncologii = Issues of Oncology 2023;69(3S):482–3. (In Russ.).
  111. Heslop H.E., Slobod K.S., Pule M.A. et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010;115(5):925–35. doi: 10.1182/blood-2009-08-239186
  112. Cui X., Snapper C.M. Epstein Barr Virus: Development of vaccines and immune cell therapy for EBV-associated diseases. Front Immunol 2021;12:734471. doi: 10.3389/fimmu.2021.734471
  113. Colby B.M., Shaw J.E., Elion G.B. et al. Effect of acyclovir 9-(2-hydroxyethoxymethyl)guanine on Epstein–Barr virus DNA replication. J Virol 1980;34(2):560–8. doi: 10.1128/jvi.34.2.560-568.1980
  114. De Clercq E. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF). Biochem Pharmacol 2016;119:1–7. doi: 10.1016/j.bcp.2016.04.015
  115. Yoshizaki T., Wakisaka N., Kondo S. et al. Treatment of locally recurrent Epstein–Barr virus-associated nasopharyngeal carcinoma using the anti-viral agent cidofovir. J Med Virol 2008;80(5):879–82. doi: 10.1002/jmv.21165
  116. Afshar K., Rao A.P., Patel V. et al. Use of foscarnet therapy for EBV infection following control of PTLD with enhancement of cellular immunity in a lung-transplant recipient. J Transplant 2011;2011:919651. doi: 10.1155/2011/919651
  117. Cohen J.I. Vaccine development for Epstein–Barr virus. Adv Exp Med Biol 2018;1045:477–93. doi: 10.1007/978-981-10-7230-7_22
  118. Bu W., Joyce M.G., Nguyen H. et al. Immunization with components of the viral fusion apparatus elicits antibodies that neutralize Epstein–Barr virus in b cells and epithelial cells. Immunity 2019;50(50):1305–16e6. doi: 10.1016/j.immuni.2019.03.010
  119. Taylor G.S., Jia H., Harrington K. et al. A recombinant modified vaccinia ankara vaccine encoding Epstein–Barr virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer. Clin Cancer Res 2014;20(19):5009–22. doi: 10.1158/1078-0432.CCR-14-1122-T
  120. Smith C., Tsang J., Beagley L. et al. Effective treatment of metastatic forms of Epstein–Barr virus-associated nasopharyngeal carcinoma with a novel adenovirus-based adoptive immunotherapy. Cancer Res 2012;72(5):1116–25. doi: 10.1158/0008-5472.CAN-11-3399
  121. Van Zyl D.G., Tsai M.H., Shumilov A. et al. Immunogenic particles with a broad antigenic spectrum stimulate cytolytic T cells and offer increased protection against EBV infection ex vivo and in mice. PLoS Pathog 2018;14(12):e1007464. doi: 10.1371/journal.ppat.1007464
  122. Chakravorty S., Yan B., Wang C. et al. Integrated pan-cancer map of EBV-associated neoplasms reveals functional host-virus interactions. Cancer Res 2019;79(23):6010–23. doi: 10.1158/0008-5472.CAN-19-0615
  123. Xu M., Yao Y., Chen H. et al. Genome sequencing analysis identifies Epstein–Barr virus subtypes associated with high risk of nasopharyngeal carcinoma. Nat Genet 2019;51(7):1131–6. doi: 10.1038/s41588-019-0436-5
  124. SoRelle E.D., Dai J., Reinoso-Vizcaino N.M. et al. Time-resolved transcriptomes reveal diverse B cell fate trajectories in the early response to Epstein–Barr virus infection. Cell Rep;40(9):111286. doi: 10.1016/j.celrep.2022.111286

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2026 Sakharnov N.A., Utkin O.V., Dmitriev S.P., Filatova E.N., Zinoviev S.V., Suslov N.A., Gamayunov S.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-57560 от  08.04.2014.